Skip to main content

View full-text article in PMC

. 2020 Oct 19;8(2):e001403. doi: 10.1136/jitc-2020-001403

Table 3.

Summary of the objective response rate (ORR) in the pembrolizumab cohort and chemotherapy cohort according to the baseline BMI and ΔBMI

	Objective response rate
	Pembrolizumab cohort		χ² test	Chemotherapy cohort		χ² test
	Response-ratio	ORR (%) (95% CI)	χ² test	Response-ratio	ORR (%) (95% CI)	χ² test
BMI (kg/m²)
Underweight (≤18.5)	10/35	28.6 (13.7–52.5)	p=0.0077 p=0.0910*	5/15	33.3 (10.8–77.8)	p=0.0758 p=0.3079*
Normal weight (18.5–25)	201/467	43.0 (37.3–49.4)		96/199	48.2 (39.1–58.9)
Overweight (25–30)	97/232	41.8 (33.9–51.0)		54/149	36.2 (27.2–47.3)
Obese (≥30)	61/106	57.5 (44.0–73.9)		29/57	50.9 (34.1–73.1)
ΔBMI
≥1.4%	116/173	67.1 (55.4–80.4)	p<0.0001	72/119	60.5 (47.3–76.2)	p<0.0001*
<1.4%	227/548	41.4 (36.2–47.2)	p<0.0001	111/292	38.0 (31.2–45.8)	p<0.0001*

*χ² test for trend.

BMI, Body mass index.